FDA pushes orforglipron decision date to April 10 as priority voucher reviews slip
A later FDA decision on Lilly's obesity pill orforglipron would leave Novo Nordisk's newly launched oral Wegovy alone on the market longer, as Medicare opens broad obesity drug coverage in April.
The Food and Drug Administration has moved its target decision date for Eli Lilly's oral obesity drug orforglipron to April 10, 2026, according to internal regulatory documents reported Jan. 15 [1]. That is later than the March 28 date agency leaders had pushed for, but still ahead of the original May 20 deadline for the drug [1]. It is one of four delays among drugs awarded the FDA's Commissioner's National Priority Voucher.
That voucher program launched in June 2025 and was meant to cut review times from the standard 10 to 12 months down to one or two months [1]. The first vouchers went out in October 2025, to Sanofi's Tzield and Disc Medicine's bitopertin, among others; Lilly and Boehringer Ingelheim won theirs in a second cycle in November [1]. The program has no statutory deadline, because it has never been authorized by Congress, BioPharma Dive reported [2].
For orforglipron, the target date has shifted in reporters' accounts. Reuters first named a March 28 decision date in December 2025, saying agency leaders wanted a verdict before the original May 20 deadline [1]. The new April 10 date comes from internal documents Reuters reviewed [1]. At the J.P. Morgan Healthcare Conference on Jan. 14, Lilly CEO David Ricks said he expects a second-quarter decision and described a "rapid review" that is "moving at pace" [2].
Three other voucher recipients also slipped. Sanofi's type 1 diabetes therapy Tzield had its review extended by more than a month after the FDA detected safety signals including two seizures, one episode of blood clotting and one death, Reuters reported [1]. A Sanofi spokesperson told BioSpace that "the assessment of the patient death is ongoing, and no causal relationship to Tzield has been established at this time," adding that blood clotting and seizures have "no known causal association" to the drug based on the company's safety database [1]. Disc Medicine's bitopertin, for the rare blood disorder porphyria, was delayed two additional weeks amid questions about its efficacy data and its risk of being abused [1]. Boehringer Ingelheim's zongertinib, proposed for non-small cell lung cancer, is now expected to get a decision in mid-February; what its original target date was has not been reported [1].
Why it matters for patients
Orforglipron is an experimental pill, and if approved it would compete with injected GLP-1 medicines such as Zepbound (tirzepatide) and Wegovy (semaglutide) [2]. Novo Nordisk launched an oral version of Wegovy in the week before Jan. 14 [2]. Medicare is set to have broad access to obesity medications beginning in April, a change a second-quarter Lilly launch would line up with [2].
Ricks said pills may be a first option for people who do not want to inject themselves, may help with staying on treatment and maintaining weight loss already achieved, and avoid the cold storage that injected drugs require [2]. Lilly's online pharmacy served 1 million people in 2025, and Ricks said cash-pay services will be central to selling orforglipron [2].
What the documents do not cover: orforglipron's price, whether insurers would cover it, and its launch timing after any approval have not been disclosed. And because the voucher program has no statutory deadline, the April 10 target is not a legal guarantee [2].
What happens next
The reported target date for orforglipron is April 10, 2026 [1], while Lilly says it expects a decision in the second quarter [2]. Boehringer's zongertinib decision is expected in mid-February [1]. Medicare's broader obesity drug coverage begins in April [2].
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.